Custom Search

coolmristuff3

Thursday, November 14, 2013

Pianissimo™ unparalleled noise reduction with Toshiba.

Turn down the sound. Turn up patient satisfaction
Do you hear that? It's the sound of patient experience transforming with Pianissimo™,
the industry's quietest noise-reduction technology. While other machines offer solutions to
mask imaging noise, Pianissimo has pioneered the way in diminishing sound at the source.
See the difference...Toshiba Medical
Pianissimo provides unparalleled noise reduction that is standard on every system so you can focus on a smoother, more accurate exam. Suffice it to say, silence has never been so intense.
Click Here
Learn more about Pianissimo at RSNA,
booth #7330 in North Hall (B).
Toshiba Medical
©Toshiba America Medical Systems 2013. All rights reserved.
Design and specifications are subject to change without notice.
YouTubeyoutube/ToshibaMedicalTwitter@ToshibaMedical

Tuesday, November 12, 2013

Half dose of MRI contrast feasible for rheumatoid arthritis

A half dose of the MRI contrast agent gadobenate dimeglumine provides just as much relevant diagnostic information as a full dose in 3-tesla imaging of patients with early rheumatoid arthritis, according to a study published in the July issue of Radiology.







The researchers did find, however, that the full dose of gadobenate dimeglumine had significantly better signal-to-noise and contrast-to-noise ratios than the half dose. The mean signal-to-noise ratio was 42.91 for the half dose, compared with 54.22 for the full dose, while the mean contrast-to-noise ratio was 12.81 for the half dose, compared with 24.78 for the full dose.
T1-weighted, fat-saturated, postcontrast 3-tesla MRI shows a half dose (a) and a full dose (b) of gadobenate dimeglumine in a 47-year-old man with early rheumatoid arthritis. The tendon sheath of the flexor tendons illustrates increased synovial enhancement, with tenosynovitis of the second flexor tendon scored as grade 3 (arrows) at both half dose and full dose. Images courtesy of Radiology.
Despite the disparity in contrast-to-noise and signal-to-noise ratios between the dosages, the diagnostic quality of the images was not affected, according to the authors. No region of synovial inflammation seen on full-dose contrast-enhanced MRI was missed at half dose.




source http://www.auntminnie.com/index.aspx?sec=sup&sub=mri&pag=dis&itemId=103913

CE credits here: Emerging Concepts in Atypical Femoral Fracture Causes, Characteristics, and Imaging



http://courses.icpme.us/class_learn?course=334


Tuesday • December 10, 2013
7:00 pm EASTERN / 6:00 pm CENTRAL / 5:00 pm MOUNTAIN / 4:00 pm PACIFIC

To enroll in this activity, click on the ENROLL NOW icon to the left.
Course Overview
Although there is strong evidence that bisphosphonates prevent certain types of osteoporotic fractures, there are concerns that these medications may be associated with rare atypical femoral fractures (AFF).1
Since many physicians including radiologists are not aware of this entity, the incidence is likely underreported. These fractures usually occur in the subtrochanteric and mid-diaphyseal regions of the femur in the setting of low-energy trauma. Awareness of these atypical fractures and their radiological appearance should enable their early and accurate detection and thus lead to specific management.2
This lecture will review current research on atypical femoral fractures, followed by case studies that focus on early radiological appearance for accurate detection of changes associated with the spectrum of AFF using plain film, DXA, and CT.
1. Gedmintas LSolomon DHKim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis. J Bone Miner Res. 2013;28(8):1729-1737.
2. Shane EBurr DAbrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2013 May 28. doi: 10.1002/jbmr.1998. [Epub
Educational Objectives
At the conclusion of this activity, participants should be better able to:
  • Discuss the potential relationship between long-term bisphosphonate (BP) therapy and atypical femoral fracture (AFF)
  • Recognize the radiographic features that distinguish AFFs from ordinary osteoporotic femoral fracture
  • Use appropriate imaging techniques, including the use of plain film, dual-energy x-ray absorptiometry (DXA) and CT, for identifying early radiographic signs of AFF.

Accreditation & Credit
Credit CANNOT be granted for group viewing.  To receive credit, EACH attendee must sign in on a separate computer.

Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and the International Center for Postgraduate Medical Education (ICPME). PIM is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Radiologic Technologists
This program has been approved by the American Society of Radiologic Technologists (ASRT) for 1.0 hour of ARRT Category A continuing education credit.
How to Participate
This program is offered by ICPME through WebEx webinar service.
  • Click ENROLL NOW and follow the registration instructions to register with ICPME.
  • You will receive an email from ICPME confirming your registration.
  • At the end of the registration process, click on ACCESS WEBINAR to enroll with WebEx and complete the pre-course evaluation.
  • Detailed log-in instructions will be sent to you via e-mail the day of the webinar.

Monday, November 11, 2013

Researchers find unexpected genetic mosaic in the brain




(Medical Xpress)-Scientists at the University of Virginia and elsewhere have discovered that nerve cells in the brain are unexpectedly varied in their genetic makeup, a surprising finding that may help explain schizophrenia, depression, bipolar disorder, autism and other such conditions thought to be genetically linked but not yet tied to a single gene.
Researchers at U.Va.'s School of Medicine and their collaborators found that up to 41 percent of the neurons they examined displayed at least one significant variation in DNA - a percentage far greater than anticipated. This variation could be in the form of either a duplication or a deletion in the genetic code. A deletion could lead to reduced expression of the affected genes, while a duplication could lead to greater expression.
"That might be why it's been so hard to figure out the genetics of these complex diseases - because we've been building on the assumption that all the cells in there had the same genome," said Mike McConnell of U,Va.'s Department of Biochemistry and Molecular Genetics. "If we've been over- or under-representing some of the risk genes, now we might have a better understanding."
The work represents an important application of single-cell sequencing, allowing scientists to examine the genetic makeup of an individual cell. McConnell said this was, to his knowledge, the first time the approach had been applied to neurons.
Neurons, he noted, are unlike most cells, where genetic deletions and alterations occur during the cellular copying process. "For the most part, you have all these neurons you're born with and you don't really replace them. Whereas in the skin, a skin cell is there for maybe a week or two weeks, and in the intestine for less than a week. When you get mosaics in these places, that cell is gone soon. But when you get these unique genomes in neurons, then those cells stay there, and they continue to participate in that circuit forever."
More research is needed to determine exactly when and how the mosaic is occurring in neurons. "What we have observed here is surprising and potentially very important. But, in some sense, our results have raised more questions than they have answered," said U.Va. researcher Ira Hall of the Department of Biochemistry and Molecular Genetics. "For example, are neuronal genomes fundamentally different than genomes from other cell types? What is the effect of age and cell type? Do levels or specific patterns of cell-to-cell genomic variability correlate with age-dependent neuronal decline, or specific disease states? To answer these questions, we need to look at many more cells, in diverse contexts."
But the finding may offer answers to longstanding questions that have flummoxed researchers. "There are examples out there of identical twins where one has schizophrenia and the other one doesn't. One has autism and the other one doesn't," McConnell said. "These are identical twins who were raised together, they had the same nature and nurture, and it's not clear why one of them would get the disease and the other one wouldn't. And it could be because of the mosaic they wound up with in their brain."
The finding may also facilitate the development of new drugs and treatments for conditions connected to the variation. "It would be very far-fetched to think that you could actually fix the mosaic," McConnell said, "but if we can understand how the mosaic is causing disease, and identify certain genes that become overrepresented or underrepresented in the mosaic, then we could start studying those genes and perhaps find better targets for some of these diseases."
Provided by University of Virginia


Siemens Symbia Intevo SPECT/CT



Yes, we should indeed be moving toward SPECT/CT as the standard of care. But in truth, we are there, and even a cursory look at a SPECT without CT shows just how critical it is to pair the two. I'll go with Dr. Maurer's original sentiment. SPECT/CT IS the new standard of care. I'll even go way, way out on a limb, which will make the bean-counters tear their hair out, and the equipment-makers jump for joy: There is no longer any reason to buy a conventional SPECT camera; EVERY NEW GAMMA CAMERA (perhaps with a few exceptions for narrow, dedicated applications) SHOULD BE A SPECT/CT device. Period. SPECT/CT is now the de facto standard of care, and it is sheer foolishness to buy 40-year-old technology in its stead. How many PET scanners (as opposed to PET/CT) are being sold today? Just about none. 




Siemens Symbia Intevo SPECT/CT:

http://doctordalai.blogspot.com/



Sunday, November 10, 2013

MRI Interventions to Present at 2013 Canaccord Genuity Medical Technology & Diagnostics Forum


IRVINE, Calif., Nov. 5, 2013 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a commercial stage medical technology company focused on creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart, announced today that Kimble Jenkins, MRI Interventions' Chief Executive Officer, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York on Thursday, November 14, 2013. The presentation is scheduled to begin at 4:00 p.m. ET. A live webcast of the presentation will be available under the IR Calendar section of the MRI Interventions website. For those unable to listen to the live webcast, a replay will be available on MRI Interventions' website following the presentation.
About MRI Interventions


Founded in 1998, MRI Interventions (OTCQB:MRIC) is a publicly traded company creating innovative platforms for performing the next generation of minimally-invasive surgical procedures in the brain and heart. Utilizing a hospital's existing MRI suite, the company's FDA-cleared and CE-marked ClearPoint(R) system is designed to enable a range of minimally-invasive procedures in the brain. In partnership with Siemens Healthcare, MRI Interventions is developing the ClearTrace(R) system to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation. Building on the imaging power of MRI, the company's interventional platforms strive to improve patient care while reducing procedure costs and times. MRI Interventions is also working with Boston Scientific Corporation to incorporate its MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications. For more information, please visit www.MRIInterventions.com.
CONTACT: MRI Interventions, Inc. 
         David Carlson 
         (901) 522-9300 

New Knee Ligament- MSK Radiologists Beware


Two knee surgeons in Belgium have found a previously unknown ligament in the centre of the human knee (pictured horizontally). The new ligament - marked by the arrows below the blue box - has been called the anterolateral ligament and 97 per cent of people are thought to have one. (LCL stands for lateral collateral ligament) The researchers, who have been investigating the injuries for four years, began by studying an 1879 article by the French surgeon Paul Segond who speculated about the existence of an additional ligament located in the centre of the front part of the knee.

Image source and more details BBC News


Monday, October 28, 2013

How does an MRI work?

Ever wonder how an works? explains in this 60-second video:

Sunday, October 27, 2013

Multitransmit for body MRI: Is it worth it?


October 18, 2013 -- At higher field strengths, the hope is for new technology to lead to more clinical applications benefiting from homogeneous MR images, but can it ever be cost-effective? That was the main question addressed during a round table discussion at the recent meeting of the European Society of MR in Medicine and Biology (ESMRMB) in Toulouse, France.

At the session, experts outlined the promise of parallel transmit (pTX) whole-body MRI and how it is already improving abdominal and prostate cancer detection and changing individual patient outcomes. The next couple of years will be a learning curve in understanding how independent pTX channels can improve image quality and change patient or even MR management, and future clinical systems could include eight, 16, or even 32 channels at field strengths of up to 7 tesla, they believe.
"We are only at the beginning of the journey," said Dr. Stefan Haneder, the section chief of vascular and abdominal imaging at the Institute of Clinical Radiology and Nuclear Medicine at University Medical Center Mannheim in Germany and a panel speaker during a discussion focusing primarily on the cost benefits of pTX whole-body MRI.

read more at 

Become an MRI Insider! When AuntMinnieEurope gets hot new information on MRI, MRI Insiders are the first to find out. Receive exclusive e-mail updates on your favorite new 


coolmristuff

ARCHIVE

MRI Nueroarm Video